Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 2;135(1):e188018.
doi: 10.1172/JCI188018.

Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention

Affiliations

Type 2 immunity to the rescue: enhancing antitumor immunity for skin cancer prevention

Matthew D Vesely et al. J Clin Invest. .

Abstract

Cutaneous squamous cell carcinoma (cSCC) incidence and deaths continue to rise, underscoring the need for improved cSCC prevention. Elimination of actinic keratosis (AK) precursor lesions is a major strategy to prevent cSCC. Topical calcipotriol and 5-fluorouracil (5-FU) have been shown to eliminate AKs and reduce the risk of cSCC development, but the mechanism was undefined. In this issue of the JCI, Oka et al. demonstrate that type 2 immunity is necessary and sufficient for the elimination of premalignant keratinocytes and cSCC prevention. Paired biopsies from AK lesions and unaffected skin revealed that only keratinocytes from AKs produced thymic stromal lymphopoietin (TSLP) and damage-associated molecular patterns, resulting in selective recruitment of Th2 cells to the AK lesion. In mouse models of skin carcinogenesis, TSLP was necessary to recruit Th2 cells and trigger IL-24-mediated keratinocyte cell death. These findings suggest that the TSLP/Th2/IL-24 axis is a potential therapeutic target for SCC prevention.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: MDV has served as an advisor for SunPharma. SRC has served as an investigator for Sol-Gel Technologies and a consultant for Inhibitor Therapeutics and Castle Biosciences.

Figures

Figure 1
Figure 1. Topical calcipotriol plus 5-FU stimulates immune surveillance in actinic keratosis and squamous cell carcinoma.
Sun-damaged skin harbors areas of normal epidermis mixed with areas of actinic keratosis, composed of transformed keratinocytes with dysregulated proliferation and differentiation, due to UV-induced somatic mutations. Topical calcipotriol induces TSLP production by transformed keratinocytes in actinic keratosis but not in unaffected keratinocytes. TSLP is recognized by T cells in the dermis and stimulates Th2 differentiation. Keratinocyte injury, mediated by the chemotherapeutic agent 5-FU, leads to expression of damage-associated molecular patterns including Annexin A1, Calreticulin, and MHC class II, which further promote T cell activation and proliferation. Activated Th2 cells secrete IL-4 and IL-13, which specifically stimulate transformed keratinocytes to express IL-24. IL-24 acts in an autocrine and paracrine fashion on transformed keratinocytes to enhance apoptosis, autophagy, and general cell death. In addition, ongoing stimulation of dermal T cells facilitates development of resident memory T cells (TRM) in the skin, allowing for long-term immunosurveillance and elimination of squamous cell carcinoma and its precursors.

Comment on

  • T helper 2 cell–directed immunotherapy eliminates precancerous skin lesions

Similar articles

References

    1. Wysong A. Squamous-cell carcinoma of the skin. N Engl J Med. 2023;388(24):2262–2273. doi: 10.1056/NEJMra2206348. - DOI - PubMed
    1. Aggarwal P, et al. United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019. J Am Acad Dermatol. 2021;85(2):388–395. doi: 10.1016/j.jaad.2021.03.109. - DOI - PubMed
    1. Karia PS, et al. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013;68(6):957–966. doi: 10.1016/j.jaad.2012.11.037. - DOI - PubMed
    1. Wehner MR, et al. Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma. JAMA Dermatol. 2015;151(4):382–388. doi: 10.1001/jamadermatol.2014.3307. - DOI - PubMed
    1. Levine DE, et al. Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study. JAMA Dermatol. 2015;151(11):1220–1225. doi: 10.1001/jamadermatol.2015.1702. - DOI - PubMed

MeSH terms